Skip to main content

Ensysce Biosciences, Inc.

corporate_fare Company Profile

Ensysce Biosciences, Inc.

ENSC·NASDAQ·Life Sciences·CIK 0001716947

Ensysce Biosciences, Inc. is a clinical stage pharmaceutical company focused on developing innovative solutions for severe pain relief. The company aims to reduce the potential for opioid misuse, abuse, and overdose. Ensysce Biosciences is currently developing product candidates designed to improve the safety of prescription drugs. Its primary focus is on opioid pain products and opioid use disorder products. The company was originally incorporated in Delaware in April 2003 as PharmacoFore, Inc., changing its name to Signature Therapeutics Inc. in January 2012. In December 2015, Signature merged with Ensysce Biosciences, Inc. ("Former Ensysce"). In June 2021, Former Ensysce merged with Leisure Acquisition Corporation, which then changed its name to Ensysce Biosciences, Inc. The principal executive office is located at 7946 Ivanhoe Avenue, Suite 201, La Jolla, California 92037.

Ensysce Biosciences, Inc. (NASDAQ:ENSC) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 25 items for ENSC at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • Director Curtis Rosebraugh Resigns from Ensysce Biosciences Board
  • Ensysce Biosciences Initiates Pivotal Phase 3 for PF614, Advances MPAR with FDA Breakthrough Therapy Support
  • Director Resigns Over Disagreement on Substantial Executive Retention Packages
  • Ensysce Biosciences Receives Nasdaq Delisting Notice for Sub-$1.00 Bid Price
  • Ensysce Shareholders Approve Significant Dilution from Financing and Expanded Equity Plan

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$5.07M
Net Income
-$10.18M
Diluted EPS
-$3.98
Op. Cash Flow
-$7.81M
Free Cash Flow
-$7.93M
Operating Income
-$10.24M
Cash & Equivalents
$4.31M
Debt / Equity
0.00×
Net Margin
-200.8%
Shares Outstanding
4.57M sh
Source: 10-K · filed 2026-03-30 · accession 0001493152-26-013633
$0.3952 +0.00% today
52-week range · as of 2026-08-25 $0.23 – $2.75
Market cap
$7.69M
Volume
174K (0.3× avg)
3-mo avg 557.2K
Live data · 2026-10-05 05:56 UTC · Market overnight

show_chartPrice Chart

Loading chart...

feed ENSC - Filings & News (Page 2)

ENSC
Apr 03, 2026, 4:14 PM EDT
Filing Type: 8-K
Importance Score:
7
Director Curtis Rosebraugh Resigns from Ensysce Biosciences Board
Price at Filing: $0.575
Real-time Price: $0.3952 info
Change: -$0.1798 (-31%) info
Market Cap: $7.685M info
Sentiment: Neutral
View Wiseek Article
ENSC
Mar 30, 2026, 4:50 PM EDT
Source: Access Newswire
Importance Score:
7
Ensysce Biosciences Initiates Pivotal Phase 3 for PF614, Advances MPAR with FDA Breakthrough Therapy Support
Price at Filing: $0.5051
Real-time Price: $0.3952 info
Change: -$0.1099 (-22%) info
Market Cap: $7.685M info
Sentiment: Positive
View Wiseek Article
ENSC
Mar 27, 2026, 5:47 PM EDT
Filing Type: 8-K
Importance Score:
8
Director Resigns Over Disagreement on Substantial Executive Retention Packages
Price at Filing: $0.5275
Real-time Price: $0.3952 info
Change: -$0.1323 (-25%) info
Market Cap: $7.685M info
Sentiment: Negative
View Wiseek Article
ENSC
Feb 27, 2026, 4:30 PM EST
Filing Type: 8-K
Importance Score:
9
Ensysce Biosciences Receives Nasdaq Delisting Notice for Sub-$1.00 Bid Price
Price at Filing: $0.6451
Real-time Price: $0.3952 info
Change: -$0.2499 (-39%) info
Market Cap: $7.685M info
Sentiment: Negative
View Wiseek Article
ENSC
Jan 08, 2026, 5:14 PM EST
Filing Type: 8-K
Importance Score:
8
Ensysce Shareholders Approve Significant Dilution from Financing and Expanded Equity Plan
Price at Filing: $1.06
Real-time Price: $0.3952 info
Change: -$0.6648 (-63%) info
Market Cap: $7.685M info
Sentiment: Negative
View Wiseek Article
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets